177 related articles for article (PubMed ID: 31234886)
1. Cost-effectiveness analysis of long-course oxaliplatin and bolus of fluorouracil based preoperative chemoradiotherapy vs. 5x5Gy radiation plus FOLFOX4 for locally advanced resectable rectal cancer.
Wang S; Wen F; Zhang P; Wang X; Li Q
Radiat Oncol; 2019 Jun; 14(1):113. PubMed ID: 31234886
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
3. Dose escalation of preoperative short-course radiotherapy followed by neoadjuvant chemotherapy in locally advanced rectal cancer: protocol for an open-label, single-centre, phase I clinical trial.
Zhang MX; Li XB; Guan BJ; Guan GX; Lin XY; Wu XD; Chi P; Xu BH
BMJ Open; 2019 Mar; 9(3):e025944. PubMed ID: 30904869
[TBL] [Abstract][Full Text] [Related]
4. Preoperative long-course chemoradiotherapy plus adjuvant chemotherapy versus short-course radiotherapy without adjuvant chemotherapy both with delayed surgery for stage II-III resectable rectal cancer: 5-Year survival data of a randomized controlled trial.
Kairevičė L; Latkauskas T; Tamelis A; Petrauskas A; Paužas H; Žvirblis T; Jaruševičius L; Saladžinskas Ž; Pavalkis D; Jančiauskienė R
Medicina (Kaunas); 2017; 53(3):150-158. PubMed ID: 28690144
[TBL] [Abstract][Full Text] [Related]
5. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
Rödel C; Liersch T; Becker H; Fietkau R; Hohenberger W; Hothorn T; Graeven U; Arnold D; Lang-Welzenbach M; Raab HR; Sülberg H; Wittekind C; Potapov S; Staib L; Hess C; Weigang-Köhler K; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R;
Lancet Oncol; 2012 Jul; 13(7):679-87. PubMed ID: 22627104
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Short-Course Radiation Therapy vs Long-Course Chemoradiation for Locally Advanced Rectal Cancer.
Raldow AC; Chen AB; Russell M; Lee PP; Hong TS; Ryan DP; Cusack JC; Wo JY
JAMA Netw Open; 2019 Apr; 2(4):e192249. PubMed ID: 30977859
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
8. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract][Full Text] [Related]
9. Randomized Controlled Trial of Neoadjuvant Short-Course Radiotherapy Followed by Consolidation Chemotherapy Versus Long-Course Chemoradiotherapy in Locally Advanced Rectal Cancer: Comparison of Overall Response Rates.
Amariyil A; Pathy S; Sharma A; Kumar S; Pramanik R; Bhoriwal S; Pandey RM
J Gastrointest Cancer; 2024 Mar; 55(1):373-382. PubMed ID: 37702850
[TBL] [Abstract][Full Text] [Related]
10. Preoperative sequential short-course radiation therapy and FOLFOX chemotherapy versus long-course chemoradiotherapy for locally advanced rectal cancer: a multicenter, randomized controlled trial (SOLAR trial).
Kang MK; Park SY; Park JS; Kim HJ; Kim JG; Kang BW; Baek JH; Cho SH; Seo AN; Kim DW; Kim J; Baek SJ; Kim JH; Kim JY; Ha GW; Park EJ; Park IJ; Kim CH; Kang H; Choi GS
BMC Cancer; 2023 Nov; 23(1):1059. PubMed ID: 37923987
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials.
Wen F; Yao K; Du ZD; He XF; Zhang PF; Tang RL; Li Q
World J Gastroenterol; 2014 Dec; 20(47):17976-84. PubMed ID: 25548497
[TBL] [Abstract][Full Text] [Related]
12. Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.
Deng Y; Chi P; Lan P; Wang L; Chen W; Cui L; Chen D; Cao J; Wei H; Peng X; Huang Z; Cai G; Zhao R; Huang Z; Xu L; Zhou H; Wei Y; Zhang H; Zheng J; Huang Y; Zhou Z; Cai Y; Kang L; Huang M; Peng J; Ren D; Wang J
J Clin Oncol; 2016 Sep; 34(27):3300-7. PubMed ID: 27480145
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.
Chongqing T; Liubao P; Xiaohui Z; Jianhe L; Xiaomin W; Gannong C; Siying W; Lihui O; Ziying Z
Pharmacoeconomics; 2014 Mar; 32(3):235-43. PubMed ID: 23709451
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
[TBL] [Abstract][Full Text] [Related]
15. High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial.
Vestermark LW; Jensen HA; Pfeiffer P
Acta Oncol; 2012 Mar; 51(3):311-7. PubMed ID: 22248062
[TBL] [Abstract][Full Text] [Related]
16. Does the addition of oxaliplatin to preoperative chemoradiation benefit cT4 or fixed cT3 rectal cancer treatment? A subgroup analysis from a prospective study.
Wiśniowska K; Nasierowska-Guttmejer A; Polkowski W; Michalski W; Wyrwicz L; Pietrzak L; Rutkowski A; Malinowska M; Kryński J; Kosakowska E; Zwoliński J; Winiarek M; Olędzki J; Kuśnierz J; Zając L; Bednarczyk M; Szczepkowski M; Tarnowski W; Paśnik K; Radziszewski J; Partycki M; Bęczkowska K; Styliński R; Wierzbicki R; Bury P; Jankiewicz M; Paprota K; Lewicka M; Ciseł B; Skórzewska M; Mielko J; Danek A; Nawrocki G; Sopyło R; Kępka L; Bujko K;
Eur J Surg Oncol; 2016 Dec; 42(12):1859-1865. PubMed ID: 27546011
[TBL] [Abstract][Full Text] [Related]
17. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
Mullins CD; Hsiao FY; Onukwugha E; Pandya NB; Hanna N
Cancer; 2012 Jun; 118(12):3173-81. PubMed ID: 22020739
[TBL] [Abstract][Full Text] [Related]
18. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study.
Bujko K; Wyrwicz L; Rutkowski A; Malinowska M; Pietrzak L; Kryński J; Michalski W; Olędzki J; Kuśnierz J; Zając L; Bednarczyk M; Szczepkowski M; Tarnowski W; Kosakowska E; Zwoliński J; Winiarek M; Wiśniowska K; Partycki M; Bęczkowska K; Polkowski W; Styliński R; Wierzbicki R; Bury P; Jankiewicz M; Paprota K; Lewicka M; Ciseł B; Skórzewska M; Mielko J; Bębenek M; Maciejczyk A; Kapturkiewicz B; Dybko A; Hajac Ł; Wojnar A; Leśniak T; Zygulska J; Jantner D; Chudyba E; Zegarski W; Las-Jankowska M; Jankowski M; Kołodziejski L; Radkowski A; Żelazowska-Omiotek U; Czeremszyńska B; Kępka L; Kolb-Sielecki J; Toczko Z; Fedorowicz Z; Dziki A; Danek A; Nawrocki G; Sopyło R; Markiewicz W; Kędzierawski P; Wydmański J;
Ann Oncol; 2016 May; 27(5):834-42. PubMed ID: 26884592
[TBL] [Abstract][Full Text] [Related]
19. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
20. Preoperative chemoradiotherapy with oxaliplatin and tegafur-uracil in locally advanced rectal cancer: pathologic complete response rate and preliminary results of overall and disease-free survival in a single institute in Taiwan.
Chao JY; Wang HM; Chiang FF; Lin JC; Chang CF; Lin JF; Yeh HL
J Chin Med Assoc; 2014 Mar; 77(3):128-32. PubMed ID: 24398439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
